Investors call on chemical firms to phase out toxic substances
The group of 43 investors, with four trillion dollars in assets under management, warned that the sector is not acting fast enough to protect vital ecosystems and human health.
In a statement released on Thursday, they urged companies, including agrochemical producers, to commit to aligning their business and political strategies with globally agreed targets.
This includes the UN Kunming-Montreal Global Biodiversity Framework and Global Framework on Chemicals, which focus on protecting nature and tackling environmental harm caused by chemicals and waste.
The investors say companies must enhance their sharing of information on how their business impacts biodiversity as well as develop strategies to transition to making products that are safe and sustainable.
Failing to address chemical pollution exposes companies and their investors to financial risks, they argued.
The group highlighted how increased public awareness and scientific understanding of the long-term health and environmental consequences of chemicals has led to a rise in litigation and regulation.
The statement has been co-ordinated by responsible investment group ShareAction, Achmea Investment Management, ChemSec, Erste Asset Management, IEHN of Clean Production Action, Planet Tracker and Mercy Investment Services.
Signatories include BNP Paribas Asset Management, Rathbones Group, Caisse des Depots et Consignations, SVVK-ASIR, Swedbank Robur and Impax Asset Management.
It comes as Government officials, business leaders, scientists and campaigners gather in Uruguay this week for discussions on the next phase in the UN Global Framework on Chemicals.
Alexandra Pinzon, head of biodiversity at ShareAction, said: 'Chemical companies have a huge role to play in curbing pollution, which would help address the interlinked crises of biodiversity loss and climate change.
'The majority of manufactured products, from fertilisers and paints to make-up and clothes, rely on chemicals, but the toxicity and pollution associated with these chemicals is wreaking havoc on ecosystems and damaging human health.'
Julie Gorte, senior vice president for sustainable investing at Impax Asset Management, said: 'This statement on the importance of tackling pollution and biodiversity loss has never been more welcome.
'If we want to avoid a planetary catastrophe, we must all act to achieve a circular economy and eliminate the pollution that is one of the major drivers of biodiversity loss.'
Arthur van Mansvelt, senior engagement specialist at Achmea Investment Management, said: 'This statement shows investors are deeply concerned that the chemicals sector is not sufficiently mitigating the risks related to biodiversity loss from pollution.'
In a separate policy-focused statement, more than 40 investors with nearly four trillion dollars in assets under management also highlighted the crucial role that regulation plays in enabling the transition of the chemicals industry to safe and sustainable products.
The group outlined recommendations for governments around the world to strengthen and harmonise global policy frameworks on chemicals to support this transition.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Bunge Global SA Just Beat EPS By 134%: Here's What Analysts Think Will Happen Next
Bunge Global SA (NYSE:BG) just released its latest quarterly results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 2.8% to hit US$13b. Bunge Global also reported a statutory profit of US$2.61, which was an impressive 134% above what the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the twin analysts covering Bunge Global are now predicting revenues of US$64.1b in 2025. If met, this would reflect a substantial 26% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 6.4% to US$7.33. Before this earnings report, the analysts had been forecasting revenues of US$52.7b and earnings per share (EPS) of US$7.70 in 2025. Although revenue sentiment looks to be improving, the analysts have made a small dip in per-share earnings estimates, perhaps acknowledging the investment required to grow the business. View our latest analysis for Bunge Global The consensus price target was unchanged at US$88.00, suggesting the business is performing roughly in line with expectations, despite some adjustments to profit and revenue forecasts. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Bunge Global's growth to accelerate, with the forecast 59% annualised growth to the end of 2025 ranking favourably alongside historical growth of 3.9% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.2% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Bunge Global is expected to grow much faster than its industry. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Bunge Global. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that in mind, we wouldn't be too quick to come to a conclusion on Bunge Global. Long-term earnings power is much more important than next year's profits. We have analyst estimates for Bunge Global going out as far as 2026, and you can see them free on our platform here. You still need to take note of risks, for example - Bunge Global has 4 warning signs (and 2 which can't be ignored) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Bloomberg
12 minutes ago
- Bloomberg
Starlink Dominates as Low Earth Orbit Satellite Race Intensifies
The story of satellites is that of a natural monopoly. The satellite market in low Earth orbit is rapidly expanding, led by Starlink's massive constellation of over 7,600 satellites. While the long-term market potential is estimated to exceed $100 billion by 2035, the economics are challenging for other players in the space. High launch and replacement costs, limited consumer demand in remote areas, and rising geopolitical competition put first-place out of reach for other players, even if they play important roles in global access. (Source: Bloomberg)


Bloomberg
12 minutes ago
- Bloomberg
EM Funds Adjust Bets as ‘Sell the Dollar' Trade Loses Appeal
The dollar's bounceback in July is convincing some emerging-market investors to bet it will keep rising in coming months. T. Rowe Price Group Inc. says it now favors dollar-denominated emerging market bonds rather than local-currency ones as a tactical trade. Barclays Plc is telling its clients to avoid shorting the greenback versus its Asian peers, while Fidelity International says the higher-for-longer US interest rates make it less attractive to borrow the dollar to fund carry trades.